• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

145.95 -3.33 (-2.23%)
Streaming Delayed Price Updated: 3:39 PM EDT, Sep 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,303,710
Open 148.94
Bid (Size) 145.91 (200)
Ask (Size) 145.96 (200)
Prev. Close 149.28
Today's Range 145.81 - 149.27
52wk Range 78.03 - 156.92
Shares Outstanding 2,531,374,696
Dividend Yield 2.33%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Stay informed with the top movers within the dow jones index on Wednesday. ↗
Today 15:10 EDT
Via Chartmill
News headline image
Prediction: Moderna Stock Will Soar 100% by 2030 ↗
Today 14:25 EDT
The company could enter a fresh growth phase. 
Via The Motley Fool

Performance

YTD
+37.1%
+37.1%
1 Month
-1.2%
-1.2%
3 Month
+13.6%
+13.6%
6 Month
+21.3%
+21.3%
1 Year
+85.7%
+85.7%

More News

Read More
News headline image
2 Outstanding Dividend Stocks to Buy and Hold for a Decade ↗
Today 13:20 EDT
Via The Motley Fool
Topics Artificial Intelligence
Uncover the latest developments among dow jones stocks in today's session. ↗
Today 12:40 EDT
Via Chartmill
News headline image
3 Healthcare Dividend Stocks Offering More Than Just Income ↗
Today 11:35 EDT
Via MarketBeat
News headline image
Merck's Tulisokibart Met Primary and Key Secondary Endpoints in Phase 2b Study in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
Today 8:15 EDT
From Merck & Co., Inc.
Via Business Wire
News headline image
SCHD's Top Sector Bet Is Healthcare at 20.7%. I'm Not Sure What's More Surprising: What It Doesn't Hold, or What It Does. ↗
Today 6:50 EDT
Via The Motley Fool
Topics ETFs Stocks
News headline image
3 Cash-Producing Stocks with Open Questions
Today 0:33 EDT
Via StockStory
Which dow jones stocks are moving on Tuesday? ↗
September 29, 2026
Via Chartmill
News headline image
Unpacking Q2 Earnings: Merck (NYSE:MRK) In The Context Of Other Branded Pharmaceuticals Stocks
September 28, 2026
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Merck Enters into Exclusive Global License Agreement with SciBrunch Therapeutics for SPR2015, an Investigational Oral KRAS G12D (ON) Inhibitor
September 28, 2026
From Merck & Co., Inc.
Via Business Wire
Friday's session: top gainers and losers in the dow jones index ↗
September 25, 2026
Via Chartmill
News headline image
U.S. FDA Approves WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC)
September 25, 2026
From Merck & Co., Inc.
Via Business Wire
Stay informed with the top movers within the dow jones index on Thursday. ↗
September 24, 2026
Via Chartmill
Thursday's session: top gainers and losers in the dow jones index ↗
September 24, 2026
Via Chartmill
News headline image
Merck’s Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2b/3 BRUNELLO Study of Adults with Diabetic Macular Edema
September 24, 2026
From Merck & Co.
Via Business Wire
Wednesday's session: top gainers and losers in the dow jones index ↗
September 23, 2026
Via Chartmill
Stay informed with the top movers within the dow jones index on Wednesday. ↗
September 23, 2026
Via Chartmill
News headline image
3 Healthcare Stocks with Warning Signs
September 23, 2026
Via StockStory
Tuesday's session: top gainers and losers in the dow jones index ↗
September 22, 2026
Via Chartmill
Uncover the latest developments among dow jones stocks in today's session. ↗
September 22, 2026
Via Chartmill
News headline image
U.S. FDA Approves Update to the Label for WINREVAIR™ (sotatercept-csrk) to Include Data from the Phase 3 HYPERION Trial Evaluating Adults Recently Diagnosed with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension)
September 22, 2026
From Merck & Co., Inc.
Via Business Wire
Meta's Muse Sends the Nasdaq to a Record and Rekindles the AI Trade ↗
September 22, 2026
Via Chartmill
Topics Artificial Intelligence
News headline image
BioNTech Stock Recently Got Downgraded. But Is Wall Street Underestimating Its Cancer Pipeline? ↗
September 22, 2026
Via The Motley Fool
News headline image
3 Reasons to Sell MRK and 1 Stock to Buy Instead
September 22, 2026
Via StockStory
Topics Stocks

Frequently Asked Questions

Is Merck & Co publicly traded?
Yes, Merck & Co is publicly traded.
What exchange does Merck & Co trade on?
Merck & Co trades on the New York Stock Exchange
What is the ticker symbol for Merck & Co?
The ticker symbol for Merck & Co is MRK on the New York Stock Exchange
What is the current price of Merck & Co?
The current price of Merck & Co is 145.95
When was Merck & Co last traded?
The last trade of Merck & Co was at 09/30/26 03:39 PM ET
What is the market capitalization of Merck & Co?
The market capitalization of Merck & Co is 369.45B
How many shares of Merck & Co are outstanding?
Merck & Co has 369B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap